No Data
Baiyang Pharmaceutical (301015.SZ): Related debts passively constitute financial support after selling the equity of the controlling subsidiary.
On December 27, Gelonghui reported that Baiyang Medicine (301015.SZ) announced that its holding subsidiary, Peking Baiyang Guosheng Medical Instruments Co., Ltd. (referred to as "Baiyang Guosheng"), has sold its 57% stake in Qingdao Baiyang Shenghui Medical Devices Co., Ltd. (referred to as "Baiyang Shenghui") as of December 2024. After this transaction is completed, Baiyang Guosheng will no longer hold shares in Baiyang Shenghui, and Baiyang Shenghui will no longer be included in the company's consolidated financial statements. As of the share transfer settlement date, the company and its subsidiary Baiyang Guosheng, along with Peking Baiyang Zhihuo Medical Results Transformation Service Co., Ltd. (hereinafter referred to as "Baiyang Zhihuo"), are for the.
Baiyang Pharmaceutical (301015.SZ): Appointed Li Zhen as the company's Deputy General Manager, Chief Financial Officer, and Secretary of the Board of Directors.
On December 23, Gelonghui reported that Baiyang Pharmaceutical (301015.SZ) announced that, after review by the company's Board of Directors' nomination committee, the Board of Directors agreed to appoint Mr. Li Zhen as the company's Vice General Manager, Chief Financial Officer, and Secretary of the Board of Directors, with the term starting from the date of approval in the twenty-eighth meeting of the third Board of Directors until the expiration date of the third Board of Directors' term.
Wang Guoqiang, the CFO of Baiyang Medicine (301015.SZ), has resigned.
Baiyang Pharmaceuticals (301015.SZ) announced that the company's Board of Directors recently received Mr. Wang Guoqiang's written resignation letter. ...
Baiyang Pharmaceutical (301015.SZ): Plans to increase capital by 24.2904 million yuan to Zhongshan Anshi.
On December 10, Gelonghui reported that Baiyang Pharmaceuticals (301015.SZ) announced that according to business development needs, its subsidiary, Ansai Pharmaceutical (Zhongshan) Co., Ltd. (hereinafter referred to as "Zhongshan Ansai"), intends to increase its registered capital from 26.65738 million yuan to 100 million yuan, with an additional registered capital of 73.34262 million yuan, which will be proportionally increased by all shareholders according to their shareholding ratios. The company and its wholly-owned subsidiary, Baiyang Group Limited (hereinafter referred to as "Baiyang Limited"), intend to increase their investment in Zhongshan Ansai by 2.42 according to their shareholding ratio.
Qingdao Baheal Medical (SZSE:301015) Is Aiming To Keep Up Its Impressive Returns
Baiyang Medical (301015.SZ): Currently has established a presence in the high-end medical instrument field with Atricure's atrial fibrillation treatment devices, and products like the full magnetic suspension artificial heart from Tongxin Medical.
HealthTimes reported on November 28th that Baiyang Pharmaceuticals (301015.SZ) stated in a recent investor relations event that the company has currently laid out Atricure's atrial fibrillation treatment equipment, Syncardia's fully magnetically levitated artificial heart, Medisense's ultrasound-guided electromagnetic positioning puncture device, and Wecare's home ECG monitor in the high-end medical instruments field; recently, the company has obtained the exclusive commercial operation rights of ZAP Surgical's ZAP-X Mars Rover radiotherapy surgical robot in mainland China and Hong Kong-Macao region.
Shareholders Are Optimistic That Qingdao Baheal Medical (SZSE:301015) Will Multiply In Value
